ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

@article{Wakeling2002ZD1839A,
  title={ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.},
  author={Alan E. Wakeling and Simon P. Guy and Jim R Woodburn and Susan Elizabeth Ashton and B. Jane Curry and Andrew J. Barker and Keith H Gibson},
  journal={Cancer research},
  year={2002},
  volume={62 20},
  pages={5749-54}
}
The epidermal growth factor receptor (EGFR) is a promising target for anticancer therapy because of its role in tumor growth, metastasis and angiogenesis, and tumor resistance to chemotherapy and radiotherapy. We have developed a low-molecular-weight EGFR tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (Iressa(2) ). ZD1839, a substituted anilinoquinazoline, is a potent EGFR-TKI (IC(50) = 0.033 micro M) that selectively inhibits EGF-stimulated tumor cell growth (IC(50) = 0.054 micro M) and that… CONTINUE READING
Highly Influential
This paper has highly influenced 16 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 319 extracted citations

Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 8 Excerpts
Highly Influenced

Quinazoline derivatives: synthesis and bioactivities

Chemistry Central journal • 2013
View 5 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2000
View 4 Excerpts
Highly Influenced

A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2001
View 1 Excerpt

Similar Papers

Loading similar papers…